Table 2.
Baseline characteristics of 4602 HIV-infected persons ever enrolled in the Johns Hopkins Clinical Cohort who had at least one clinical visit, CD4 cell count or HIV viral load July 1, 2000–June 30, 2012, stratified by self-report of injection drug use as their likely route of HIV acquisition
| N | PWID 1659 |
Non-IDU 2943 |
Total 4602 |
|---|---|---|---|
| Male sexa | 1104 (67 %) | 1922 (65 %) | 3026 (66 %) |
| Ageb | 42 (37, 48) | 39 (32, 46) | 40 (34, 47) |
| Race | |||
| Black | 1365 (82 %) | 2106 (72 %) | 3471 (75 %) |
| White | 273 (16 %) | 702 (24 %) | 975 (21 %) |
| Other | 21 (1 %) | 135 (5 %) | 156 (3 %) |
| HIV acquisition risk | |||
| MSM | 142 (9 %) | 1077 (37 %) | 1219 (26 %) |
| Heterosexual | 756 (46 %) | 1640 (56 %)s | 2396 (52 %) |
| History of any antiretroviral use |
865 (52 %) | 1512 (51 %) | 2377 (52 %) |
| AIDS | 465 (28 %) | 767 (26 %) | 1232 (27 %) |
| CD4 cell count (cells/µL)b |
285 (115, 486) | 280 (98, 477) | 282 (105, 480) |
| <50 | 232 (14 %) | 494 (17 %) | 726 (16 %) |
| 50–199 cells/µL | 366 (22 %) | 609 (21 %) | 975 (21 %) |
| 200–349 | 371 (22 %) | 587 (20 %) | 958 (21 %) |
| ≥350 cells/µL | 636 (38 %) | 1153 (39 %) | 1789 (39 %) |
| Missing | 54 | 100 | 154 |
| Viral load (HIV RNA log10 copies/mL)b |
4.3 (3.0, 4.9) | 4.3 (2.9, 5.0) | 4.3 (3.0, 5.0) |
| Missing | 194 | 286 | 480 |
HIV human immunodeficiency virus, PWID persons who inject drugs, IDU injection drug use, MSM men who have sex with men, ART antiretroviral therapy, AIDS acquired immune deficiency syndrome
a
N (%) unless otherwise specified
b
Median (IQR)